Core Viewpoint - A class action securities lawsuit has been filed against KBR, Inc. alleging securities fraud that affected investors between May 6, 2025, and June 19, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that KBR, Inc. made false statements regarding its partnership with HomeSafe, despite knowing that the U.S. Department of Defense had concerns about HomeSafe's ability to fulfill a global household goods contract [2]. - It is alleged that the defendants' statements about KBR's business operations and prospects were materially false and misleading [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until November 18, 2025, to request to be appointed as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Law Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - A class action securities lawsuit has been filed against WPP plc, alleging securities fraud that negatively impacted investors between February 27, 2025, and July 8, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that WPP provided overly positive statements while concealing material adverse facts about its media arm's ability to handle macroeconomic challenges and competition, leading to a loss of market share [2] - On July 9, 2025, WPP reported a deterioration in performance for Q2 2025, attributing this to macroeconomic uncertainty and weaker new business, partly due to ongoing restructuring within WPP Media [2] - Following the trading update, WPP's stock price fell from $35.82 per share on July 8, 2025, to $29.34 per share on July 9, 2025, marking an approximate decline of 18.1% in one day [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until December 8, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4]

Core Viewpoint - V.F. Corporation is facing a class action securities lawsuit due to alleged securities fraud that negatively impacted investors between October 30, 2023, and May 20, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that V.F. Corporation made materially false and misleading statements regarding its turnaround plans, particularly concerning the Vans brand, which required significant reset actions to return to growth [2]. - Following the release of V.F. Corporation's fiscal 2025 results on May 21, 2025, it was revealed that Vans' revenue growth trajectory had significantly declined, with losses increasing from 8% to 20% in the fourth quarter [2]. - The company's results were attributed to deliberate actions taken to eliminate unprofitable businesses, which were previously unannounced, and even without these actions, Vans would have shown a high single-digit revenue decline [2]. Group 2: Stock Price Impact - On May 21, 2025, V.F. Corporation's stock price fell from $14.43 to $12.15 per share, marking a decline of approximately 15.8% in one day following the negative news [2]. Group 3: Next Steps for Investors - Investors who suffered losses during the relevant period have until November 12, 2025, to request to be appointed as lead plaintiff in the lawsuit, although participation does not require serving in this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 4: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [4].

Core Viewpoint - Baxter International, Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, primarily related to systemic defects in its Novum IQ Large Volume Pump, which posed serious risks to patients [1][3]. Summary by Sections Class Action Lawsuit Details - The class action lawsuit is titled Electrical Workers Pension Fund, Local 103, I.B.E.W. v. Baxter International, Inc., and covers purchasers of Baxter common stock from February 23, 2022, to July 30, 2025 [1]. - Investors have until December 15, 2025, to seek appointment as lead plaintiff in the lawsuit [1]. Allegations Against Baxter - The lawsuit alleges that Baxter made false or misleading statements regarding the Novum IQ Large Volume Pump, which suffered from systemic defects leading to malfunctions such as underinfusion and overinfusion [3]. - Baxter was reportedly aware of multiple device malfunctions and injuries but failed to take adequate remedial measures [3]. - The company announced on July 31, 2025, a voluntary and temporary pause in shipments and installations of the Novum LVP, which led to a more than 22% drop in its stock price [4]. Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Baxter common stock during the class period to seek lead plaintiff status [5]. - The lead plaintiff represents the interests of all class members and can select a law firm to litigate the case [5]. About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [6]. - The firm has a strong track record, being ranked 1 in securing monetary relief for investors in securities class action cases [6].

Core Viewpoint - A federal securities fraud class action lawsuit has been filed against LifeMD, alleging misleading representations regarding its financial health and growth prospects, following a significant stock price decline after its earnings report in August 2025 [1]. Summary by Sections Lawsuit Details - The lawsuit, titled Johnston v. LifeMD, Inc., covers the period from May 7, 2025, to August 5, 2025, claiming that LifeMD made false statements, particularly during its first-quarter results announcement on May 6, 2025, when it raised its full-year revenue and adjusted EBITDA guidance [2]. - The complaint asserts that LifeMD's optimistic outlook regarding its competitive position in virtual obesity care and the performance of its RexMD brand was misleading, as it did not disclose significant operational challenges [2]. Operational Challenges - The lawsuit highlights that LifeMD faced increasing customer acquisition costs in its RexMD segment and a higher-than-expected refund rate in its weight management business, which were not disclosed to investors [3]. Stock Price Impact - The alleged misleading information came to light on August 5, 2025, when LifeMD reported second-quarter results that missed revenue and earnings per share estimates, leading to a reduction in its full-year guidance. The company's management attributed this to "temporary elevated customer acquisition costs" and refund issues, resulting in a stock price drop of over 44% the following day [4]. Investor Recovery - For investors who incurred significant losses during the specified period, the lawsuit presents an opportunity for potential recovery of damages [5]. Investigation by Hagens Berman - Hagens Berman, a national plaintiffs' rights firm, is investigating the claims against LifeMD, focusing on whether the company was aware of but failed to disclose key operational issues [6].

Core Viewpoint - The Law Offices of Howard G. Smith is announcing a securities fraud class action lawsuit against Marex Group plc, inviting investors who have suffered substantial losses to participate in the lawsuit [1][2]. Summary by Sections Lawsuit Details - The lawsuit alleges that between May 16, 2024, and August 5, 2025, Marex Group plc failed to disclose critical information to investors, including: 1. The Company sold over-the-counter financial instruments to itself 2. There were inconsistencies in financial statements between subsidiaries and related parties, particularly regarding intercompany receivables and loans 3. As a result, Marex's financial statements were unreliable 4. Consequently, the positive statements made by the defendants about the Company's business and prospects were materially misleading and lacked a reasonable basis [3]. Participation Information - Investors who wish to participate in the class action must contact the Law Offices of Howard G. Smith before December 8, 2025, which is the lead plaintiff deadline [2]. - Interested parties can reach out via email, phone, or visit the law firm's website for more information [4]. Class Action Membership - To be a member of the class action, no immediate action is required; investors may choose to retain counsel or remain absent from the action [5].

Core Insights - Johnson Fistel, PLLP is investigating Zions Bancorporation for potential violations of federal securities laws related to misleading statements and undisclosed material information [1] - A Bloomberg report on October 16, 2025, indicated that Zions and another regional bank faced losses from fraudulent loans linked to distressed commercial real estate, resulting in a stock price drop of over 13% [2] Company Overview - Zions Bancorporation is under scrutiny for its lending practices and risk management controls following allegations of fraud [2] - The investigation by Johnson Fistel aims to determine if Zions' officers and directors failed to disclose critical information to investors [1] Legal Context - Investors who purchased Zions securities and experienced significant losses are encouraged to participate in the investigation led by Johnson Fistel [3] - Johnson Fistel is recognized for its role in securities class actions and has a history of recovering substantial amounts for investors [5]

Core Viewpoint - A class action lawsuit has been filed against aTyr Pharma, Inc. regarding allegations of securities fraud and unlawful business practices [2][4]. Group 1: Lawsuit Details - The lawsuit involves claims that aTyr and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors have until December 8, 2025, to request to be appointed as Lead Plaintiff if they purchased aTyr securities during the Class Period [2]. Group 2: Company Performance - On September 15, 2025, aTyr announced that its EFZO-FIT study did not meet its primary endpoint, leading to a significant drop in stock price [4]. - Following the announcement, aTyr's stock price fell by $5.01 per share, or 83.17%, closing at $1.01 per share [5]. Group 3: Company Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering multimillion-dollar damages for class members [6].

Core Points - aTyr Pharma, Inc. is facing a class action securities lawsuit due to alleged securities fraud that occurred between January 16, 2025, and September 12, 2025 [1] - The lawsuit claims that aTyr misled investors regarding the efficacy of its drug Efzofitimod, particularly its ability to allow patients to taper steroid usage [2] - The stock price of aTyr plummeted by 83.2%, from $6.03 on September 12, 2025, to $1.02 on September 15, 2025, following the announcement that the EFZO-FIT study did not meet its primary endpoint [2] Case Details - The complaint alleges that the defendants provided overly positive statements while concealing material adverse facts about the drug's efficacy [2] - The EFZO-FIT study's failure to meet its primary endpoint was disclosed during an investor call on September 15, 2025, prompting the stock price decline [2] - aTyr plans to engage with the FDA to determine the next steps after the disappointing study results [2] Next Steps - Investors who suffered losses during the relevant time frame have until December 8, 2025, to request to be appointed as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4] - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]

Accessibility StatementSkip Navigation NEW YORK, Oct. 17, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Lantheus investors who were adversely affected by alleged securities fraud between February 26, 2025 and August 5, 2025. Follow the link below to get more information and be contacted by a member of our team: https: ...